Tags

Type your tag names separated by a space and hit enter

A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors.
J Clin Psychopharmacol. 2005 Oct; 25(5):413-8.JC

Abstract

To thoroughly investigate the phenomenon of atypical antipsychotic associated weight gain, a feeding laboratory paradigm was developed. This study is a randomized, double-blind, parallel group trial comparing the tolerability and effects of a two-week exposure to olanzapine, risperidone or placebo on weight, resting energy expenditure (REE), and eating behaviors in 48 healthy human subjects. Subjects were randomized to receive olanzapine, risperidone, or placebo and titrated over four days to 10 mg/d, or 4 mg/d, respectively. The mean dose at endpoint was 8.75 mg/day for the olanzapine group and 2.88 mg/d risperidone group. Weight changes were significantly different between groups at midpoint (F = 5.477, df = 2, 44, P = .0001). The olanzapine group demonstrated a significant increase in weight at midpoint (1.59 + 1.80 kg, P = .002) and endpoint (2.25 + 1.62 kg, P = .0001) compared to placebo and at endpoint compared to risperidone (1.05 + 1.15 kg, P = .015). Resting energy expenditures corrected for fat free mass did not reveal any differences between groups. Olanzapine subjects demonstrated significantly more dry mouth and sedation versus placebo while risperidone subjects experienced significantly more sedation, dry mouth, dizziness stuffy nose and restlessness than placebo and more dizziness and stuffy nose versus olanzapine subjects. Thus, a human feeding lab paradigm utilizing a brief exposure to atypical antipsychotics functions as a method to investigate pharmacologically induced weight gain.

Authors+Show Affiliations

Department of Clinical Neuroscience, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND 58107, USA. jroerig@nrifargo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16160615

Citation

Roerig, James L., et al. "A Comparison of the Effects of Olanzapine and Risperidone Versus Placebo On Eating Behaviors." Journal of Clinical Psychopharmacology, vol. 25, no. 5, 2005, pp. 413-8.
Roerig JL, Mitchell JE, de Zwaan M, et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J Clin Psychopharmacol. 2005;25(5):413-8.
Roerig, J. L., Mitchell, J. E., de Zwaan, M., Crosby, R. D., Gosnell, B. A., Steffen, K. J., & Wonderlich, S. A. (2005). A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. Journal of Clinical Psychopharmacology, 25(5), 413-8.
Roerig JL, et al. A Comparison of the Effects of Olanzapine and Risperidone Versus Placebo On Eating Behaviors. J Clin Psychopharmacol. 2005;25(5):413-8. PubMed PMID: 16160615.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. AU - Roerig,James L, AU - Mitchell,James E, AU - de Zwaan,Martina, AU - Crosby,Ross D, AU - Gosnell,Blake A, AU - Steffen,Kristine J, AU - Wonderlich,Stephen A, PY - 2005/9/15/pubmed PY - 2005/12/13/medline PY - 2005/9/15/entrez SP - 413 EP - 8 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 25 IS - 5 N2 - To thoroughly investigate the phenomenon of atypical antipsychotic associated weight gain, a feeding laboratory paradigm was developed. This study is a randomized, double-blind, parallel group trial comparing the tolerability and effects of a two-week exposure to olanzapine, risperidone or placebo on weight, resting energy expenditure (REE), and eating behaviors in 48 healthy human subjects. Subjects were randomized to receive olanzapine, risperidone, or placebo and titrated over four days to 10 mg/d, or 4 mg/d, respectively. The mean dose at endpoint was 8.75 mg/day for the olanzapine group and 2.88 mg/d risperidone group. Weight changes were significantly different between groups at midpoint (F = 5.477, df = 2, 44, P = .0001). The olanzapine group demonstrated a significant increase in weight at midpoint (1.59 + 1.80 kg, P = .002) and endpoint (2.25 + 1.62 kg, P = .0001) compared to placebo and at endpoint compared to risperidone (1.05 + 1.15 kg, P = .015). Resting energy expenditures corrected for fat free mass did not reveal any differences between groups. Olanzapine subjects demonstrated significantly more dry mouth and sedation versus placebo while risperidone subjects experienced significantly more sedation, dry mouth, dizziness stuffy nose and restlessness than placebo and more dizziness and stuffy nose versus olanzapine subjects. Thus, a human feeding lab paradigm utilizing a brief exposure to atypical antipsychotics functions as a method to investigate pharmacologically induced weight gain. SN - 0271-0749 UR - https://www.unboundmedicine.com/medline/citation/16160615/A_comparison_of_the_effects_of_olanzapine_and_risperidone_versus_placebo_on_eating_behaviors_ L2 - https://doi.org/10.1097/01.jcp.0000177549.36585.29 DB - PRIME DP - Unbound Medicine ER -